Former FDA Senior Reviewer Dr. Jinhui Dou Joins Deep Intelligence as Chief Advisor Amid IPO Filing

VCBeat (WeChat Official Account: vcbeat) has learned that Deep Intelligence recently announced the appointment of Dr. Dou Jinhui, a former senior FDA review expert, as its Chief Advisor. With over three decades of experience in pharmaceutical scientific research and FDA regulatory review, Dr. Dou’s addition will further strengthen Deep Intelligence’s global one-stop solutions for pharmaceutical R&D, including regulatory consulting, content management, regulatory operations, and pharmacovigilance across China, the United States, Japan, Europe, and other regions.

Dr. Dou Jinhui holds a Ph.D. in Pharmaceutics from the University of Mississippi and has earned widespread acclaim across industry, regulatory, and academic sectors. He previously served as Deputy Director of the Research Institute at Yiling Pharmaceutical. Prior to that, he was a Senior Expert in Pharmacology and Pharmacognosy at the U.S. Food and Drug Administration (FDA), where he led the Botanical Drug Review Team within the Center for Drug Evaluation and Research (CDER). During his tenure at the FDA from 2002 to 2017, Dr. Dou received the CDER Team Excellence Award six times, the FDA Team Honor Award once, and the Superior Service Award from the U.S. Department of Health and Human Services once. Dr. Dou has also served as a Senior Scientist in Natural Product Development at NaPro BioTherapeutics, a Postdoctoral Fellow in Medicinal Chemistry at the University of Kansas, and a Lecturer in Chinese Materia Medica Identification at Beijing University of Chinese Medicine.

During his tenure at the FDA’s Center for Drug Evaluation and Research (CDER), Dr. Dou contributed to the development of industry guidance and regulations concerning dietary supplements, botanical drug development, complementary and alternative medicines, and combination or co-packaged pharmaceutical products. As a senior reviewer in pharmacognosy and pharmacology/toxicology, he participated in the review and approval of multiple New Drug Applications (NDAs) for botanical and chemical drugs, as well as over five hundred Investigational New Drug (IND) applications for clinical trials. Dr. Dou also engaged in the safety and quality assessment of various Section 503A compounded medications, over-the-counter (OTC) drugs, drug-device combination products, and dietary supplements.

In addition to Dr. Dou Jinhui, Deep Intelligence has recently established an industry expert team that includes four Japanese pharmaceutical experts. With the addition and expansion of this international top-tier expert team, Deep Intelligence will continue to advance its global practice of AI-driven new drug R&D, empowering clients to accelerate their progress on the global R&D stage.

DeepBrain AI is a high-tech innovation company dedicated to empowering the entire new drug R&D process with artificial intelligence technologies on a global scale, helping global pharmaceutical companies and their service providers accelerate their transition toward intelligent operations. The company is committed to building an end-to-end AI-driven new drug R&D platform that empowers and accelerates global pharmaceutical enterprises in bringing drugs from the laboratory to the market with high quality and efficiency. Its team consists of AI experts from top internet companies and pharmaceutical R&D specialists from multinational pharmaceutical corporations. DeepBrain AI’s independently developed AI intelligent systems and related services cover the entire chain of new drug R&D, including drug discovery, organic synthesis, clinical trials, pharmacovigilance, regulatory submissions, and medical translation.

In September 2018, DeepBiosciences secured nearly $15 million in exclusive Series B financing from Sequoia Capital. The company is currently conducting operations and R&D simultaneously in China, the United States, and Japan, serving nearly 100 leading pharmaceutical and medical device companies, CROs, and third-party institutions worldwide.